Rockefeller Capital Management’s Emergent Biosolutions EBS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$7.89K Sell
941
-115
-11% -$962 ﹤0.01% 4102
2026
Q1
$8.77K Buy
1,056
+861
+442% +$8.92K ﹤0.01% 4051
2025
Q4
$2.41K Buy
+195
New +$2.09K ﹤0.01% 4270
2023
Q1
– Sell
-101
Closed -$1K – 2492
2022
Q4
$1K Sell
101
-56
-36% -$867 ﹤0.01% 3669
2022
Q3
$3K Sell
157
-70
-31% -$1.95K ﹤0.01% 3474
2022
Q2
$7K Sell
227
-16
-7% -$546 ﹤0.01% 3288
2022
Q1
$9K Buy
+243
New +$10.7K ﹤0.01% 3099
2021
Q4
– Sell
-200
Closed -$10K – 3821
2021
Q3
$10K Sell
200
-12
-6% -$727 ﹤0.01% 2883
2021
Q2
$13K Buy
212
+12
+6% +$771 ﹤0.01% 2661
2021
Q1
$18K Sell
200
-600
-75% -$61.5K ﹤0.01% 2323
2020
Q4
$71K Sell
800
-119
-13% -$10.9K ﹤0.01% 1565
2020
Q3
$94K Sell
919
-44
-5% -$4.74K ﹤0.01% 1281
2020
Q2
$76K Buy
963
+510
+113% +$38K ﹤0.01% 1269
2020
Q1
$26K Buy
453
+240
+113% +$13.8K ﹤0.01% 1423
2019
Q4
$11K Hold
213
– – ﹤0.01% 1576
2019
Q3
$11K Sell
213
-14
-6% -$652 ﹤0.01% 1387
2019
Q2
$11K Sell
227
-136
-37% -$6.52K ﹤0.01% 1198
2019
Q1
$18K Buy
+363
New +$21.4K ﹤0.01% 1280

Other funds holding EBS

Rockefeller Capital Management's EBS Position: Q2 2026 in Review

Rockefeller Capital Management reduced its Emergent Biosolutions (EBS) stake by 11% in Q2 2026, selling an estimated $962 and leaving 941 shares worth $7.89K. The position accounts for ﹤0.01% of the portfolio, ranked #4102.

Rockefeller Capital Management first reported a position in EBS in Q1 2019 and has held it in 18 quarters since. The position peaked at $94K in Q3 2020. 194 funds tracked by Wall St. Rank hold EBS as of Q2 2026.

  • Rockefeller Capital Management held 941 shares of Emergent Biosolutions worth $7.89K as of Q2 2026.
  • Rockefeller Capital Management sold 115 Emergent Biosolutions shares in Q2 2026, an estimated $962.
  • Emergent Biosolutions made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #4102 holding.
  • Rockefeller Capital Management first reported a position in Emergent Biosolutions in Q1 2019 and has held it in 18 quarters since.
  • Rockefeller Capital Management's Emergent Biosolutions position peaked at $94K in Q3 2020.
  • 194 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.